Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
1999/09/01 by Jan M. M. Walboomers, Jan M.M. Walboomers, Marcel V. Jacobs +10 · 44 citations
Medicine · #Cervical Cancer and HPV Research #Hepatitis B Virus Studies #Genital Health and Disease
paper · doi:10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f
Abstract
A recent report that 93 per cent of invasive cervical cancers worldwide contain human papillomavirus (HPV) may be an underestimate, due to sample inadequacy or integration events affecting the HPV L1 gene, which is the target of the polymerase chain reaction (PCR)-based test which was used. The formerly HPV-negative cases from this study have therefore been reanalyzed for HPV serum antibodies and HPV DNA. Serology for HPV 16 VLPs, E6, and E7 antibodies was performed on 49 of the 66 cases which were HPV-negative and a sample of 48 of the 866 cases which were HPV-positive in the original study. Moreover, 55 of the 66 formerly HPV-negative biopsies were also reanalyzed by a sandwich procedure in which the outer sections in a series of sections are used for histological review, while the inner sections are assayed by three different HPV PCR assays targeting different open reading frames (ORFs). No significant difference was found in serology for HPV 16 proteins between the cases that were originally HPV PCR-negative and -positive. Type-specific E7 PCR for 14 high-risk HPV types detected HPV DNA in 38 (69 per cent) of the 55 originally HPV-negative and amplifiable specimens. The HPV types detected were 16, 18, 31, 33, 39, 45, 52, and 58. Two (4 per cent) additional cases were only HPV DNA-positive by E1 and/or L1 consensus PCR. Histological analysis of the 55 specimens revealed that 21 were qualitatively inadequate. Only two of the 34 adequate samples were HPV-negative on all PCR tests, as against 13 of the 21 that were inadequate ( p< 0.001). Combining the data from this and the previous study and excluding inadequate specimens, the worldwide HPV prevalence in cervical carcinomas is 99.7 per cent. The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer. The extreme rarity of HPV-negative cancers reinforces the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
Cited by
- Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities
- Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica
- Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2
- Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6
- Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme
- Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions
- Analysis of Risk-Structured Vaccination Model for the Dynamics of Oncogenic and Warts-Causing HPV Types
- Second primary cancers in survivors of cervical cancer in the Netherlands: Implications for prevention and surveillance
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases
- HPV-negative tumors of the uterine cervix
- Viruses, Periodontitis, and Systemic Diseases
- Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer
- T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates
- Human Papillomavirus Type and Clinical Manifestation in Seven Cases of Large-cell Neuroendocrine Cervical Carcinoma
- Estimating the Age of Disease-causal HPV Infection Based on the Natural History of CIN2+ Among Females in Canada
- RETRACTED ARTICLE: IGF2 is Deregulated During the Development of Uterine Cervical Carcinoma in Indian Patients
- Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia
- Shrinkage estimation of large covariance matrices using multiple\n shrinkage targets
- Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial
- The causal relation between human papillomavirus and cervical cancer. [europepmc]
- Human papillomavirus and cervical cancer. [europepmc]
- Pathogenesis of human papillomaviruses in differentiating epithelia. [europepmc]
- Evaluating human papillomavirus vaccination programs. [europepmc]
- Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. [europepmc]
- Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. [europepmc]
- HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. [europepmc]
- The known unknowns of HPV natural history. [europepmc]
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. [europepmc]
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. [europepmc]
- Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. [europepmc]
- Mutational heterogeneity in cancer and the search for new cancer-associated genes. [europepmc]
- The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? [europepmc]
- Targeting neoantigens to augment antitumour immunity. [europepmc]
- Cytology versus HPV testing for cervical cancer screening in the general population. [europepmc]
- Opportunities and challenges for human papillomavirus vaccination in cancer. [europepmc]
- The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. [europepmc]
- Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. [europepmc]
- Tumor neoantigens: from basic research to clinical applications. [europepmc]
- Human papillomavirus and cervical cancer. [europepmc]
- Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. [europepmc]
- Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. [europepmc]
- The microbiome and gynaecological cancer development, prevention and therapy. [europepmc]
- Cervical cancer: Epidemiology, risk factors and screening. [europepmc]
- Cervical cancer therapies: Current challenges and future perspectives. [europepmc]
Related